Contact Information
David Horne, Ph.D.
  • Vice Provost and Associate Director, Beckman Research Institute
  • Chair and Professor, Molecular Medicine
  • Deputy Director for Research
  • Director, Synthetic and Biopolymer Chemistry Core
  • Co-director, Drug Discovery and Structural Biology (DDSB) Core

Biography

Biography

David Horne, Ph.D., is vice provost and associate director of Beckman Research Institute. In this role, he oversees the Irell and Manella Graduate School of Biological Sciences, the Postdoctoral Training Office, International Research Programs, Medical Education and the Office of Faculty Affairs. As part of his role as vice provost, Horne serves as Dean of Faculty Affairs. He is an institutional leader in all aspects of academic scientific and medical education in conjunction with Alexandra Levine, M.D., M.A.C.P., our chief medical officer, to help shape the scientific and educational vision for City of Hope. In addition, he assists Dr. Steven T. Rosen in his responsibilities as Beckman Research Institute director.
 
Horne is well-known for his scientific and research expertise, as well as his ability to build strong relationships with faculty and leaders across our organization and at partnering institutions.  He has held numerous leadership positions since first joining the Beckman Research Institute in 2006, including his most recent role as Interim Director.  Horne’s professional experience is complemented by impressive academic achievements that include a Ph.D. in chemistry from the Massachusetts Institute of Technology as well as a postdoctoral fellowship from the California Institute of Technology.
 

Professional Experience

  • 2014 - present, Deputy Director for Research, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2012 - present, Interim Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2011 Associate Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2011 Co-Director, Drug Discovery and Structural Biology (DDSB) Core, Beckman Research Institute of City of Hope, Duarte, CA
  • 2009 - present, Co-leader, Developmental Cancer Therapeutics Program, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2008 - present, Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2007 - 2008, Associate Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 - present, Director, Synthetic and Biopolymer Chemistry Core Facility, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 Professor, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2004 Professor of Chemistry, Oregon State University, OR
  • 1998 Associate Professor of Chemistry, Oregon State University, OR
  • 1997 Associate Professor of Chemistry, Columbia University, New York City, NY
  • 1993 Adjunct Professor, Department of Biology, Columbia University, New York City, NY
  • 1992 Assistant Professor of Chemistry, Columbia University, New York City, NY
  • 1989 NIH Postdoctoral Fellow, California Institute of Technology, Pasadena, CA

Education

 
Education/Training
 
  • 1989 NIH Postdoctoral Fellow, California Institite of Technology, Pasadena, CA
  • 1988 Massachusetts Institute of Technology, Ph.D., Chemistry
  • 1984 University of California, Los Angeles, M.S., Chemistry
  • 1983 University of California, Los Angeles, B.S., Chemistry
 

Honors/Awards

 
Awards
 
  • 2004 Olaf Boedtker Faculty Inspiration Award, College of Science, Oregon State University
  • 2002 Harris Teaching Award, Department of Chemistry, Oregon State University
  • 2001 Lloyd Carter Teaching Award, College of Science, Oregon State University
  • 1996 Great Teacher Award, Honorable Mention, Columbia University
  • 1995 National Science Foundation Young Investigator Award
  • 1993 Becton-Dickson Fellow
  • 1992 Beckman Young Investigator Award
  • 1989 National Institutes of Health Postdoctoral Fellow

Honors

  • 2011 Member, Scientific Advisory Board, Arnold and Mabel Beckman Foundation
 

Memberships


  • 2013 Chair, NIH NCATS, TRND Study Section
  • 2013 Ad hoc Member, SBIR ((Biological Chemistry, Biophysics, and Drug Discovery) Study Section
  • 2009 Ad hoc Member, National Institutes of Health F32 Study Section
  • 2007 Ad hoc Member, National Institutes of Health K99-R00 Pathway to Independence Study Section
  • 2006 Ad hoc Member, National Institutes of Health SBCA Study Section
  • 2001 - 2006, Permanent Member, National Institutes of Health MCHA/SBCA Study Section
  • 2000 Ad hoc Member, National Institutes of Health MCHA Study Section
  • 1998 Ad hoc Member, National Institutes of Health MCHA Study Section
  • 1997 Ad hoc Member, National Institutes of Health MCHA Study Section

Publications


Representative Publications
 
  • Donaldson, J. M.; Zer, C.; Avery, K. N.; Bzymek, K. P.; Horne, D. A.; Williams, J. C. “Identification and grafting of a unique peptide-​binding site in the Fab framework of monoclonal antibodies” Proc. Natl. Acad. Sci., Early Edition (2013), (Oct 7 2013), 1-6.
  • DeLorbe, J. E.; Horne, D.; Jove, R.; Mennen, S. M.; Nam, S.; Zhang, F.-L.; Overman, L. E. “General Approach for Preparing Epidithiodioxopiperazines from Trioxopiperazine Precursors: Enantioselective Total Syntheses of (+)​- and (-​)​-​Gliocladine C, (+)​-​Leptosin D, (+)​-​T988C, (+)​-​Bionectin A, and (+)​-​Gliocladin A” J. Am. Chem. Soc. 2013, 135, 4117-4128.
  • Zhou, B.; Su, L.; Hu, S.; Hu, W.; Yip, M. L. R.; Wu, J.; Gaur, S.; Smith, D. L.; Yuan, Y.-C.; Synold, T. W.; Horne, D.; Yen, Y. “A small-​molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance” Cancer Res 2013, 73, 6484-6493.
  • Lu, L.; Zhang, W.; Nam, S.; Horne, D. A.; Jove, R.; Carter, R. G. “Amphidinolide B: total synthesis, structural investigation, and biological evaluation” J. Org. Chem. 2013, 78, 2213-2247.
  • Li, Y.-J.; Perkins, A. L.; Su, Y.; Ma, Y.; Colson, L.; Horne, D. A.; Chen, Y. “Gold nanoparticles as a platform for creating a multivalent poly-​SUMO chain inhibitor that also augments ionizing radiation” Proc. Natl. Acad. Sci. 2012, 109, 4092-4097.
  • Li, W.; Tian, E.; Chen, Z.-X.; Sun, G. Q.; Ye, P.; Yang, S.; Lu, D.; Xie, J.; Ho, T.-V; Tsark, W. M.; Wang, C.; Horne, D. A.; Riggs, A. D.; Yip, M. L. R.; Shi, Y. “Identification of Oct4-​activating compounds that enhance reprogramming efficiency” Proc. Natl. Acad. Sci. 2012, 109, 20853-20858.
  • Yuan, H.; Wang, Z.; Li, L.; Zhang, H.; Modi, H.; Horne, D.; Bhatia, R.; Chen, W. “Activation of stress response gene SIRT1 by BCR-​ABL promotes leukemogenesis” Blood 2012, 119, 1904-1914
  • Tian, Y.; Nam, S.; Liu, L.; Yakushijin, F.; Yakushijin, K.; Buettner, R.; Liang, W.; Yang, F.; Ma, Y.; Horne, D.; Jove, R. “Spirooxindole derivative SOID-​8 induces apoptosis associated with inhibition of JAK2​/STAT3 signaling in melanoma cells” PLoS One 2012, 7, e4930.
  • Singhal, S. S.; Figarola, J.; Singhal, J.; Leake, K.; Nagaprashantha, L.; Lincoln, C.; Gabriel Gugiu, B.; Horne, D.; Jove, R.; Awasthi, S.; Rahbar, S. "1,3-Bis(3,5-dichlorophenyl) urea compound ‘COH-SR4’ inhibits proliferation and activates apoptosis in melanoma" Biochem. Pharmacol. 201284 (11), 1419-1427.
  • Figarola, J. L.; Weng, Y.; Lincoln, C; Horne, D.; Rahbar, S. "Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis" Invest. New Drugs 201230 (4), 1413-25.
  • Nam, S.; Xie, J.; Perkins, A.; Ma, Y.; Yang, F.; Wu, J.; Wang, Y.; Xu, R. Z.; Huang, W.; Horne, D. A.; Jove, R. "Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells" Molecular Oncology 20126 (5), 484-93.
  • Singhal, S. S.; Figarola, J.; Singhal, J.; Leake, K.; Nagaprashantha, L.; Lincoln, C.; Gabriel Gugiu, B.; Horne, D.; Jove, R.; Awasthi, S.; Rahbar, S. "1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma" Biochem. Pharmacol. 2012.
  • Xie, J.; Ma, Y.; Horne, D. A. "Asymmetric Synthesis of the Core Structure of Leucosceptroids A-D" J Org Chem 201176, 6169-76.
  • Xie, J.; Ma, Y.; Horne, D. A. "Total synthesis of the proposed structure of iriomoteolide-1a" Tetrahedron 201167, 7485-501.
  • Ma, Y.; Kowolik, C. M.; Swiderski, P. M.; Kortylewski, M.; Yu, H.; Horne, D. A.; Jove, R.; Caballero, O. L.; Simpson, A. J. G.; Lee, F. T.; Pillay, V.; Scott, A. M. "Humanized Lewis-Y Specific Antibody Based Delivery of STAT3 siRNA" ACS Chem. Biol 2011 DOI: 10.1021/cb200176v
  • Buettner, R.; Corzano, R.; Rashid, R.; Lin J. P.; Senthil, M.; Hedvat, M.; Schroeder, A.; Mao, A.; Herrmann, A.; Yim, J.; Li, H. Z.; Yuan, Y. C.; Yakushijin, K. I.; Yakushijin, F.; Vaidehi, N.; Moore, R.; Gugiu, G.; Lee, T. D.; Yip, R.; Chen, Y.; Jove, R.; Horne, D.; Williams, J. C. "Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development" ACS Chem. Biol 20116, 432-43.
  • Xie J, Ma, Y.; Horne, D. A. "Total synthesis of the proposed structure of iriomoteolide-1a" Chem. Commun. (Cambridge, U. K.) 201046, 4770-72.
  • Miyake, F.; Hashimoto, M.; Tonsiengsom, S.; Yakushijin, K.; Horne, D. A. "Synthesis of 5-(3-indolyl)oxazole natural products" Structure revision of Almazole D. Tetrahedron 2010, 66, 4888-93.
  • Ma, Y.; Nam, S.; Jove, R.; Yakushijin, K.; Horne, D. A. "Synthesis and anticancer activities of ageladine A and structural analogs" Bioorg. Med. Chem. Lett. 201020, 83-86.
  • Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; Jove, R.; Yu, H. "STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors" Nat. Med. (N. Y., NY, U. S.) 201016, 1421-28.
  • Xie, J.; Ma, Y.; Horne, D. A. "Asymmetric Synthesis of the C(7)-C(23) Fragment of Iriomoteolide-1a" Org. Lett. 200911, 5082-84.
  • Xie, J.; Horne, D. "Stereoselective synthesis of iriomoteolide-1a hemiketal core" Tetrahedron Lett. 200950, 4485-87.
  • Ma, Y.; Yakushijin, K.; Miyake, F.; Horne, D. "A concise synthesis of indolic enamides: coscinamide A, coscinamide B, and igzamide" Tetrahedron Lett. 200950, 4343-45.
  • Tonsiengsom, F.; Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Reduction of 2,5-bis(3'-indolyl)pyrazines to 2,5-bis(3'-indolyl) piperazines: synthesis of bisindolylpiperazine marine alkaloids dragmacidin A, B, and C" Synthesis 2006, 49-54.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Biomimetic synthesis of grossularines-1" Angew. Chem., Int. Ed. 200544, 3280-82.
  • Shimizu, H.; Shimizu, K.; Kubodera, N.; Yakushijin, K.; Horne, D. A. "Efficient modification of steroid 20S-hydroxy functionality for industrial preparation of 1α,25-dihydroxy-22-oxavitamin D3, Maxacalcitol" Tetrahedron Lett. 200445, 1347-50.
  • Shimizu, H.; Shimizu, K.; Kubodera, N.; Yakushijin K; Horne, D. A. "Regioselective cleavage of trisubstituted epoxy-linkage using lithium trialkylborohydride reagents: A new route to the key intermediate of maxacalcitol" Heterocycles 200463, 1335-43.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "A concise synthesis of spirotryprostatin A" Org. Lett. 20046, 4249-51.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Preparation and synthetic applications of 2-halotryptophan methyl esters: Synthesis of spirotryprostatin B" Angewandte Chemie-International Edition 200443, 5357-60.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Preparation and synthetic applications of 2-halotryptamines: Synthesis of elacomine and isoelacomine" Org. Lett. 20046, 711-13.
  • Castedo, M.; Perfettini, J. L.; Roumier, T.; Yakushijin, K; Horne, D.; Medema, R.; Kroemer, G. "The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe" Oncogene 200423, 4353-61.
  • Castedo, M.; Perfettini, J. L.; Roumier, T.; Valent, A.; Raslova, H.; Yakushijin, K; Horne, D.; Feunteun, J.; Lenoir, G.; Medema, R.; Vainchenker, W.; Kroemer, G. "Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy" Oncogene 200423, 4362-70.
  • Wiese, K. J.; Yakushijin, K.; Horne, D. A. "Synthesis of dibromophakellstatin and dibromoisophakellin" Tetrahedron Lett. 2002, 43 (29), 5135-36.
  • Miyake FY; Yakushijin, K.; Horne, D. A. "Synthesis of marine sponge bisindole alkaloids dihydrohamacanthins" Org. Lett. 20024, 941-3.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "Synthesis of axinohydantoins" J. Org. Chem. 200267, 4498-5000.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "A facile synthesis of dragmacidin B and 2,5-bis(6 '-bromo-3 '-indolyl)piperazine" Org. Lett. 20002, 3185-87.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "A concise synthesis of topsentin A and nortopsentins B and D" Org. Lett. 20002, 2121-23.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "Controlling cyclizations of 2-pyrrolecarboxamidoacetals. Facile solvation of [beta]-amido aldehydes and revised structure of synthetic homolongamide" Tetrahedron Lett. 200041, 4295-99.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "A practical synthesis of (Z)-debromohymenialdisine" J. Org. Chem. 200065, 610-1.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "Synthesis of slagenins A, B, and C" Org. Lett. 20002, 3443-44.
 

Patents

 
Representative Patents
 
  • Non-provisional patent application (USA) 14/083,938, “Photocleavable Linker” Filed: 11/19/2013.
  • PCT Application/US2013/066252 “ETP Derivatives” Filed: 10/22/2013.
  • Non-provisional patent application (USA) 13/953,013, “Novel Modulators and Development of Adipocyte and Cancer Cells” Filed: 7/29/2013.
  • Non-provisional application (USA) 13/776,374, “Isatin Derivatives, Pharmaceutical Compositions Thereof, and Methods of Use Thereof” Filed: 2/25/2013.
  • PCT Application/US2013/24490, “Synthesis of COH 29” Filed: 2/1/2013.
  • PCT Application/US2012/32938, “Meditopes and Meditope-Binding Antibodies and Uses Thereof” Filed: 4/10/2012.
  • Non-provisional patent application (USA) “Multi-Valent Poly-SUMO Chain Inhibitor and Methods of Use” 13/401,642, Filed: 2/21/2012.
  • PCT Application/US2012/23034, “Novel Modulators of Development of Adipocyte And Cancer Cells” Filed: 1/27/2012.
  • Non-provisional patent application (USA) “Humanized Lewis-Y Specific Antibody-Based Delivery of Dicer Substrate siRNA (D-siRNA) Against STAT3” 61/454,458, Filed: 3/18/2011.
  • Non-provisional patent application (USA) “Berbamine Derivatives” 12/783,535, Filed: 5/19/2010.
  • US Patent 8,163,783 “Ribonuclease Reductase Inhibitors and Methods of use” Issued: 4/25/2011.
  • US Patent 7,956,076 “Ribonuclease Reductase Inhibitors and Methods of use” Issued: 4/8/2009.
  • US Patent 7,615,638 “Synthesis of Grossularines-1 and Analogs Thereof and Method of Use” Issued: 4/30/2007.
  • U.S. Patent 6,841,658 “Methods for Making Bis-Heterocyclic Alkaloids” Issued: 1/11/2005.
  • U.S. Patent 6,211,361 “Method for Making Debromohymenialdisine and Analogs Thereof” Issued: 4/3/01.
  • U.S. Patent 6,197,954. “Intermediates for the Synthesis of Debromohymenialdisine and Processes Thereof” Issued: 3/6/01.
  • U.S. Patent 6,103,899. “Bicyclic Aminoimidazoles” Issued: 8/15/00.
  • PCT Int. Appl. (1998), WO 9809935. “Intermediates for the Synthesis of Vitamin D and Steroid Derivatives and Processes for Preparation Thereof” Issued: 3/12/98.
  • U.S. Patent 5,834,609. “Bicyclic Aminoimidazoles” Issued: 6/10/98.

Locations


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010